- Home
- DKNG vs GMAB Comparison
DKNG vs GMAB Comparison
Compare DKNG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DKNG | GMAB |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2B | 17.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DKNG | GMAB |
|---|---|---|
| Price | $34.45 | $33.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 28 | 6 |
| Target Price | ★ $47.75 | $40.40 |
| AVG Volume (30 Days) | ★ 10.7M | 1.4M |
| Earning Date | 02-12-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 132.41 |
| EPS | N/A | ★ 25.10 |
| Revenue | ★ $5,458,104,000.00 | $3,845,670,022.00 |
| Revenue This Year | $28.13 | $24.85 |
| Revenue Next Year | $22.44 | $16.51 |
| P/E Ratio | ★ N/A | $1.34 |
| Revenue Growth | 18.50 | ★ 29.57 |
| 52 Week Low | $26.23 | $17.24 |
| 52 Week High | $53.61 | $33.89 |
Technical Indicators
Market Signals| Indicator | DKNG | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 67.11 |
| Support Level | $33.68 | $31.37 |
| Resistance Level | $35.50 | $31.91 |
| Average True Range (ATR) | 1.25 | 0.58 |
| MACD | -0.06 | 0.17 |
| Stochastic Oscillator | 28.68 | 94.48 |
Price Performance
Historical ComparisonAbout DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number-two or -three revenue share position across states where it competes. DraftKings is now live with online or retail sports betting in 28 states and i-gaming in 5 states, with both products available to around 40% of Canada's population. In 2024, sports revenue was 61% of total sales, i-gaming 32%, and fantasy and lottery 7%. The company plans to launch a predictive event platform in late 2025 and also operates a non-fungible token commission-based marketplace and develops and licenses online gaming products.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.